[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626585":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Hudson Biotech","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Experimental - BPC 157","EXPERIMENTAL","Participants receive investigational pentadecapeptide BPC 157 plus standardized rehabilitation.",[13,14],"Drug: Pentadecapeptide BPC 157","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm 2: Placebo Comparator - Placebo","Participants receive matching placebo plus standardized rehabilitation.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Pentadecapeptide BPC 157","subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.",[9,16],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Placebo",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Seni S Lu, Phd","CONTACT","+86 13076790030","Seni-Lu@beijing-biotech.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Peking University Shenzhen Hospital","RECRUITING","Shenzhen","Guangdong","518036","China","CN",{"type":45,"coordinates":46},"Point",[47,48],114.0683,22.54554,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":54},"Zhen J Peng, Phd","+86 13076790039","Zhen-Peng@beijing-biotech.com",{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100626585","phase-2-bpc-157-for-acute-hamstring-muscle-strain-repair-100626585",false,"NCT07437547","BPC 157 for Acute Hamstring Muscle Strain Repair","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI","BPC-HAMSTR","Inclusion Criteria:\n\n* Age 18 to 45 years.\n* Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.\n* MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.\n* Pre-injury physical activity \\>= 3 sessions\u002Fweek or participation in organized recreational sport.\n* Willingness to follow the standardized rehabilitation protocol and attend all study visits.\n* For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose.\n\nExclusion Criteria:\n\n* Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.\n* Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.\n* Prior hamstring strain on the index limb within the past 6 months.\n* Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides\u002Fgrowth factors within 30 days prior to screening.\n* Known bleeding disorder or current therapeutic anticoagulation.\n* Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.\n* Known allergy or hypersensitivity to components of the investigational product or placebo.\n* Pregnant or breastfeeding.\n* Current participation in another interventional clinical study or participation within 30 days prior to screening.\n* Currently subject to a formal anti-doping testing program (e.g., WADA\u002FUSADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority","ALL","18 Years","45 Years",{"count":69,"type":70},120,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.",[76,77],"Hamstring Muscle Strain","Skeletal Muscle Injury",[79,80,81,82,83,84,85,86,87,88],"BPC 157","BPC-157","pentadecapeptide","muscle strain","hamstring injury","sports medicine","MRI","return to play","muscle repair","rehabilitation","2026-02-22",{"date":91,"type":92},"2026-02-27","ACTUAL",{"date":94,"type":92},"2026-02-02",{"date":96,"type":70},"2028-02-17",{"name":5,"class":6},1]